Biotech | March 01, 2022
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
High level of vaccine efficacy maintained over a 6-month period of surveillance
High level of vaccine efficacy maintained over a 6-month period of surveillance
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
The joint initiative is called J-ARC Healthcare Solutions
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Subscribe To Our Newsletter & Stay Updated
